União Europeia - português - EMA (European Medicines Agency)

mabxience research sl - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - agentes antineoplásicos - alymsys in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. alymsys in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. alymsys in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with alymsys in combination with capecitabine. alymsys, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. alymsys, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. alymsys in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. alymsys, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. alymsys, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

libbs farmacÊutica ltda - rituximabe - antineoplasico

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

ems sigma pharma ltda - hemitartarato de zolpidem - hipnoticos

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

legrand pharma indÚstria farmacÊutica ltda - hemitartarato de zolpidem - hipnoticos

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

cosmed industria de cosmeticos e medicamentos s.a. - hemitartarato de zolpidem - hipnoticos

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

momenta farmacÊutica ltda. - hemitartarato de zolpidem - hipnoticos

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

eurofarma laboratÓrios s.a. - hemitartarato de zolpidem - hipnoticos

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

supera farma laboratÓrios s.a - hemitartarato de zolpidem - hipnoticos

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

germed farmaceutica ltda - hemitartarato de zolpidem - hipnoticos

União Europeia - português - EMA (European Medicines Agency)

dopharma research b.v. - meloxicam - oxicams - pigs; calves - cattlefor uso em infecções respiratórias agudas, com terapêutica antibiótica adequada para reduzir os sinais clínicos em bovinos. para uso em diarréia em combinação com terapia de reidratação oral para reduzir sinais clínicos em bezerros com mais de uma semana de idade e bovinos jovens não lactantes. para terapia adjuvante no tratamento de mastite aguda, em combinação com terapia antibiótica. pigsfor uso em bursite locomotor transtornos para reduzir os sintomas de claudicação e inflamação. para o alívio da dor pós-operatória associada a cirurgia menor de tecidos moles, como a castração. para terapia adjuvante no tratamento de septicemia puerperal e toxemia (síndrome de mastite-metrite-agalactia) com terapia antibiótica apropriada. horsesfor usar no alívio da inflamação e aliviar a dor, tanto aguda e crônica, desordens músculo-esqueléticas. para o alívio da dor associada à cólica equina.